Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2622 - Real world use of palliative systemic therapy (tx) in patients (pts) with metastatic early onset colorectal cancer (mEOCRC) within a UK specialist cancer centre

Date

09 Sep 2017

Session

Poster display session

Presenters

Alexandros Georgiou

Citation

Annals of Oncology (2017) 28 (suppl_5): v158-v208. 10.1093/annonc/mdx393

Authors

A. Georgiou, S. Khakoo, A. Minchom, K. Kouvelakis, R. Kalaitzaki, N. Nobar, V. Calamai, M. Ifijen, M. Lethby, F. Arouri, I. Chau, D. Watkins, S. Rao, D. Cunningham, N. Starling

Author affiliations

  • Department Of Medicine  , Royal Marsden Hospital NHS Foundation Trust  , SW3 6JJ - London and Surrey/GB
More

Resources

Abstract 2622

Background

The incidence of EOCRC, defined as CRC diagnosed in pts< 50 years old, is increasing. Current literature relating to the palliative systemic tx used, its efficacy, tolerability and outcomes in this group is sparse.

Methods

Retrospective analysis of pts with mEOCRC treated with systemic tx at the Royal Marsden Hospital (RMH) between Jan 2009 – Dec 2014 was conducted.

Results

114 pts had palliative systemic tx. 93 had mEOCRC at diagnosis of whom 51% were male, median age 43 (range 21-49), 90% performance status ≤1. 72% had left (L) sided tumours. 4% had signet cells. 2 pts had known hereditary syndromes. 72% had liver, 20% peritoneal and 20% lung metastases (met). All 114 pts had ≥1 line of doublet cytotoxic tx. The most commonly administered regimens were: 15% FOLFIRI+ bevacizumab (Bev), 15% FOLFIRI, 11% CAPOX, 10% FOLFOX+ Bev. 12% of tx was given within trials. 38% of pts had tx delays and 38% dose reductions or one agent of a combination tx discontinued early, during their the first line tx. 19% had radiofrequency ablation to liver or lung met. Median overall survival (mOS) in pts presenting with mEOCRC: 18.5 months (95% C.I 14.3-22.6). In addition to BRAF mutant pts, the groups below also trended towards a lower mOS, months (95%C.I): -Younger age: Age 20-29=8.3 (2.6-28.6), 30-39=16.1 (9.6-22.6), 40-49=21.2 (14.9-27.7) -Right (R) sided tumour: R = 13.7 (8.3-18.7) vs L = 20.2 (14.9-27.7) -Signet cells =7.0 (NA) vs No signet cells =18.7 (14.3-22.6) -Fewer lines of systemic tx (Table) The majority of KRAS Wild Type (WT) pts (n = 46) had cetuximab or panitumumab. mOS was 21.7 months (95% C.I 16.0-27.7) for WT vs 15.8 months (95% C.I 9.9-21.2) in mutant pts.Table:

597P

Metastatic tx line1234
N114784015
Median PFS, months6.95.02.03.9
Best Response (%)CR 4 PR 40 SD 23 PD 32 NA 1CR 1 PR 17 SD 26 PD 51 NA 5PR 8 SD 23 PD 69PR 7 SD 13 PD 73 NA 7
mOS from diagnosis if last line of tx, months9.014.918.731.7

Conclusions

Pts treated with sequential combination systemic tx had a better mOS. However, pts with mEOCRC appear to have lower response rates, progression free survival (PFS) and OS when compared to recently published randomised trials. This suggests a more aggressive disease phenotype that warrants further research and tx development.

Clinical trial identification

Legal entity responsible for the study

Royal Marsden Hospital, UK

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.